drugset
drugset / Trial / NCT02346032

Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma

NCT02346032 ↗

Phase 2 Completed 4 enrolled Samsung Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Phase II Study of Refametinib, a MEK inhibitor, as second-line treatment in advanced biliary tract adenocarcinoma

Timeline

Start
2015-06-30
Primary completion
2016-09-30
Completion
2016-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Refametinib Small molecule 50 mg Oral

Indications

biliary tract cancer